Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2005-09-13
2005-09-13
Smith, L. J. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S164100, C424S184100, C424S185100, C424S257100, C424S234100, C530S350000, C530S388200, C530S387100, C530S388400, C435S320100, C435S069100, C435S325000, C435S252330, C435S006120, C435S410000, C435S420000
Reexamination Certificate
active
06942861
ABSTRACT:
The present invention describes the isolation and purification of histidine-tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The invention further describes the use of intimin as an antigen to promote a protective immune response. In addition, the invention describes the combination of intimin with one or more other antigens and administration of the combination to promote a protective immune response against intimin and the one or more antigens.One aspect of the invention is the administration of intimin to target specific epithelial cells to promote a protective immune response to intimin proteins. Additional aspects of the invention include the use of intimin or intimin combined with one or more antigens and administration of the combination to target gastrointestinal mucosa and stimulate an immune response. Additionally, the invention describes administration of the combination of intimin combined with drugs, to provide a means for targeted delivery of drugs to specific epithelial cells. Other aspects of the invention include the production of antibodies directed against his-intimin and methods of using such antibodies to provide passive immune protection, and in an assay system.
REFERENCES:
patent: 4141970 (1979-02-01), Chidlow et al.
patent: 4736017 (1988-04-01), O'Hanley et al.
patent: 4740585 (1988-04-01), Schmidt et al.
patent: 5049500 (1991-09-01), Arnizen et al.
patent: 5310654 (1994-05-01), Isberg et al.
patent: 5378824 (1995-01-01), Bedbrook et al.
patent: 5681736 (1997-10-01), Pace et al.
patent: 5702727 (1997-12-01), Amkraut et al.
patent: 5747293 (1998-05-01), Dougan et al.
patent: 5759551 (1998-06-01), Ladd et al.
patent: 5798260 (1998-08-01), Tarr et al.
patent: 5800821 (1998-09-01), Acheson et al.
patent: 5858352 (1999-01-01), Pace et al.
patent: 5914114 (1999-06-01), Cassels
patent: 6245892 (2001-06-01), Oaks et al.
patent: 6261561 (2001-07-01), Stewart, Jr. et al.
patent: 6277379 (2001-08-01), Oaks et al.
patent: 6406885 (2002-06-01), Stewart et al.
patent: 2002/0006407 (2002-01-01), McKee et al.
patent: 2078716 (1992-09-01), None
patent: 2078716 (1994-03-01), None
patent: 0 222 835 (1987-05-01), None
patent: 0282042 (1988-09-01), None
patent: 90/02484 (1990-03-01), None
patent: 92/02820 (1992-02-01), None
patent: 95/15678 (1994-06-01), None
patent: 94/20135 (1994-09-01), None
patent: 96/00233 (1996-01-01), None
patent: 96/12801 (1996-05-01), None
Cravioto, A et al, The Journal of Infectious Diseases, vol. 163, pp. 1247-1255, 1991.
Dean-Nystrom, E et al, 4th International Shiga toxin producingE. colimeeting, Kyoto, Japan, Oct. 2000, abstract.
Campbell, Ailsa M. Monoclonal Antibody and Immunosensor technology, Chapter 1, pp. 1-49, specifically p. 3, 1991.
Agin, TS et al, Cytotoxins, Cholera and the gut, pp. 315-320, 1995.
Cravioto, A et al, The Journal of Infectious Deseases, vol. 163, pp. 1247-1255, 1995.
Ashkenazi, S et al, J. Pediatrics, Dec. 1988, vol. 113(6), pp. 1008-10014, (abstract), 1988.
Agin, T.S et al, Cytokines, cholera and the gut, pp. 315-320, Nov., 1995, IOS, Ohmsha.
Butterton, J et al, Abstracts of the General meeting of the American society for Microbiology, vol. 95(0), May 21-25, p. 294, 1995.
Cirillo, J.D. et al, Clinical Infectious Diseases, vol. 20, pp. 101-1009, 1995.
McDonough, Sean P. et al, Am. J. Vet. Res, vol. 55, No. 11, Nov., 1994.
Cravioto et al, J. Infect. Dis., vol. 163, p 1247-1255, 1991.
Butterton, J. R. et al, Abstracts of the Gen Meeting of the Am. Soc. Microbiologists, vol. 95(0), p 294, #E77, 1995.
Lourie, M et al, Oct. 1993, Infect. Immun., vol. 61(10), p 4085-4092.
McKee et al (May 1995), Am. Soc. of Microbiol, p. 166, Abstract #B-5, Monday Session 18.
McKee, ML (1995) Dissertation Abstracts Int., vol. 56(78), p. 3583, (abstract).
Leong, J.H. et al, Jun., 1990, vol. 9(6), EMBO J., pp. 1979-1989.
Chart, H. et al, J. Clin. Microbiol, 1989, vol. 27(2), p 285-290.
Toth, I et al, J. Clin. Microbiol, 1991, vol. 29(5), p 1016-1019.
Rice, E.W. et al, J. Clin. Microbiol, 1992, vol. 30(5), p 1315-1316.
Isberg, R. B., Science, May 17, 1991, vol. 252(5008), p 934-938.
G. Frankel et al., “Intimin from EnteropathogenicEscherichia coliRestores Murine Virulence to aCitrobacter rodentiumeaeA Mutant: Induction of an Immunoglobulin A Response to Intimin and EspB,”Infection and Immunity,64(12):5315-5325 Dec. 1996.
S. Barzu et al., “Characterization of B-Cell Epitopes on IpaB, an Invasion-Associated Antigen ofShigella flexneri:Identification of an Immunodominant Domain Recognized during Natural Infection,”Infection and Immunity,61(9):3825-3831 (1993).
T.K. McDaniel et al., “A Genetic Locus of Enterocyte Effacement Conserved Among Diverse Enterobacterial Pathogens,”Proc. Natl. Acad. Sci. USA,92:1664-1668 (1995).
M. Simonet et al., “Immunization with Live aroA RecombinantSalmonella typhimuriumProducing Invasion Inhibits Intestinal Translocation ofYersinia pseudotuberculosis,” Infection and Immunity,62(3):863-867 (1994).
Abstract: Evelyn Dean-Nystrom, Lisa Gansheroff, Edda Twiddy, Harley Moon, and Alison O'Brien, “Passive Protection of Suckling Piglets FromEscherichia coliO157:H7 Infection by Vaccination of Pregnant Sows with intiminO157,”4thInternational Shiga Toxin Producing E. coli Meeting,Kyoto, Japan (Oct. 2000).
Beebakhee et al., “Cloning and Nucleotide Sequence of the eae Gene Homologue from Enterohemorrhagic Escherichia coli Serotype 0157:H7”, FEMS Microbio. Ltrs, 91:63-68 (1992).
Dalsgaard et al., “Plant-Derived Vaccine Protects Target Animals Against a Viral Disease”, Nature Biotechnology, 15:248-252 (1997).
Donnenberg et al., “The Role of the eae Gene of Enterohemorrhagic Escherichia coli in Intimate Attachment In Vitro and in a Porcine Model”,J. Clin. Invest., 92:1418-1424 (Sep. 1993).
Frankel et al., “Characterization of the C-Terminal Domains of Intimin-Like Proteins of Enteropathogenic and Enterohemorrhagic Escherichia coli, Citrobacter, and Hafnia alvei”, Infection and Immunity, 62(5):1835-1842 (May 1994).
Frankel et al., “Molecular Characterization of a Carboxy-Terminal Eukaryotic-Cell-Binding Domain of Intimin from Enteropthogenic Escherichia coli”,Infection and Immunity, 63(11):4323-4328 (Nov. 1995).
Hochuli, “Purification of Recombinant Proteins with Metal Chelate Adsorbent”,Genetic Engineering, Principles & Practice (J. Setlow, ed) Plenum, New York, 12:87-98 (1990).
Jerse and Kaper, “The eae Gene of Enteropathogenic Escherichia coli Encodes a 94-Kilodalton Membrane Protein, the Expression of Which is Influenced by the EAF Plasmid”,Infection and Immunity, 59(12):4302-4309 (Dec. 1991).
Levine et al., “The Diarrheal Response of Humans to Some Classic Serotypes of Enteropathogenic Escherichia coli is Dependent on a Plasmid Encoding an .Enteroadhesiveness Factor”, J. Infect. Dis., 152(3):550-559 (Sep. 1985).
Little et al., “Human Antibody Libraries in Escherichia coli”, J. Biotech, 41:187-195 (1995).
Louie et al., “Expression and Characterization of the eaeA Gene Product of Escherichia coli Serotype 0157:H7”, Infection and Immunity,61(10):4085-4092 (Oct. 1993).
McKee and O'Brien, “Truncated Enterohemorrhagic Escherichia coli(EHEC)0157:H7 Intimin(EaeA)Fusion Proteins Promote Adherence of EHEC Strains to HEp-2 Cells”, Infection and Immunity, 64(6):2225-2233 (Jun. 1996).
McKee et al., “EnterohemorrhagicEscherichia coli0157:H7 Requires Intimin to Colonize the Gnotobiotic Pig Instestine and to Adhere to HEp-2 Cells”, Infection and Immunity, 63(9):3739-3744 (Sep. 1995).
McKee and O'Brien, “Investigation of Enterohemorrhagic Escherichia coli 0157:H7 Adherence Characteristics and Invasion Potential Reveals a New Attachment Pattern Shared by Intestinal E. coli”, Infection and Immunity, 63(5):2070-2074 (May 1995).
Skerra, “Bacterial Express
McKee Marian L.
O'Brien Alison D.
Wachtel Marian R.
Finnegan Henderson Farabow Garrett & Dunner, LLP.
Henry M. Jackson Foundation for the Advancement of Military Medi
Portner Ginny Allen
Smith L. J.
LandOfFree
Histidine-tagged intimin and methods of using intimin to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histidine-tagged intimin and methods of using intimin to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histidine-tagged intimin and methods of using intimin to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3370953